Related Experiment Videos

[Association between inflammatory cytokine CD40 gene polymorphism and risk of acute coronary syndrome]

Cai-Xia Tian1, Yan Li, Ming Wang

  • 1Department of Clinical Laboratory Science, Renmin Hospital of Wuhan University, Wuhan 430060, China.

Zhonghua Xin Xue Guan Bing Za Zhi
|December 23, 2008
PubMed

Insights

Elevated inflammatory markers and a specific CD40 gene variant (CD40-1C/T polymorphism) are linked to increased acute coronary syndrome (ACS) risk in Han Chinese individuals. Fluvastatin demonstrated potential in inhibiting IFN-gamma-induced CD40 expression in peripheral blood mononuclear cells.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Genetics

Background:

  • Acute coronary syndrome (ACS) involves complex inflammatory processes.
  • CD40 signaling pathways play a role in cardiovascular disease pathogenesis.
  • Genetic variations may influence susceptibility to ACS.

Purpose of the Study:

  • To assess inflammatory markers (CD40, sCD40L, hs-CRP, WBC) in ACS patients.
  • To investigate the association of CD40-1C/T polymorphism with ACS risk in Han Chinese.
  • To examine the regulatory effects of IFN-gamma and fluvastatin on CD40 expression in PBMNCs.

Main Methods:

  • Recruited 160 ACS patients and 92 controls.
  • Utilized ELISA, immunoturbidimetric assay, and flow cytometry for marker detection.
  • Analyzed CD40 genotype via PCR-RFLP and DNA sequencing.
  • Cultured PBMNCs with IFN-gamma and fluvastatin to assess CD40 expression.

Main Results:

  • ACS patients exhibited significantly higher CD40, sCD40L, hs-CRP, and WBC levels.
  • The CD40-1C allele and CC genotype were associated with increased ACS risk (OR=1.608).
  • IFN-gamma upregulated CD40 expression in PBMNCs, which was inhibited by fluvastatin across genotypes.

Conclusions:

  • Elevated inflammatory cytokines are present in ACS patients.
  • CD40-1C/T polymorphism is a risk factor for ACS in the Han Chinese population.
  • IFN-gamma enhances PBMNC CD40 expression, and fluvastatin can inhibit this effect.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...